One study conducted in a New Zealand PCa cohort by Karunasinghe et al. suggested that the presence of the Q5 mutation in combination with smoking is associated with unusually low serum PSA levels that belie the severity of disease and lead to late detection by current prostate-specific antigen (PSA) diagnostic benchmarks [38]. The gene discussed is KLK3; the disease is posterior cortical atrophy.